FDx Advisors’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$206K Sell
1,481
-843
-36% -$118K 0.07% 178
2025
Q4
$285K Buy
2,324
+52
+2% +$6.32K 0.15% 70
2025
Q3
$272K Sell
2,272
-319
-12% -$36.3K 0.08% 142
2025
Q2
$287K Sell
2,591
-507
-16% -$54K 0.09% 135
2025
Q1
$347K Sell
3,098
-1,328
-30% -$137K 0.11% 112
2024
Q4
$409K Sell
4,426
-939
-18% -$84.5K 0.12% 112
2024
Q3
$450K Buy
5,365
+117
+2% +$8.93K 0.12% 113
2024
Q2
$360K Sell
5,248
-591
-10% -$39.4K 0.1% 126
2024
Q1
$428K Sell
5,839
-310
-5% -$23.8K 0.07% 226
2023
Q4
$498K Buy
6,149
+1,741
+39% +$135K 0.04% 393
2023
Q3
$330K Sell
4,408
-1,151
-21% -$88.5K 0.03% 446
2023
Q2
$428K Sell
5,559
-7,180
-56% -$573K 0.02% 493
2023
Q1
$1.09M Hold
12,739
0.05% 278
2022
Q4
$1.09M Sell
12,739
-4,297
-25% -$340K 0.05% 278
2022
Q3
$1.05M Sell
17,036
-2,053
-11% -$129K 0.05% 272
2022
Q2
$1.18M Buy
19,089
+2,867
+18% +$178K 0.04% 290
2022
Q1
$964K Buy
16,222
+291
+2% +$18.6K 0.03% 334
2021
Q4
$1.16M Sell
15,931
-893
-5% -$61.5K 0.03% 333
2021
Q3
$1.18M Sell
16,824
-149
-0.9% -$10.5K 0.04% 311
2021
Q2
$1.17M Sell
16,973
-1,749
-9% -$117K 0.04% 302
2021
Q1
$1.21M Buy
18,722
+2,366
+14% +$153K 0.05% 253
2020
Q4
$953K Buy
16,356
+3,595
+28% +$217K 0.04% 281
2020
Q3
$806K Sell
12,761
-11,739
-48% -$814K 0.04% 270
2020
Q2
$1.89M Buy
24,500
+8,296
+51% +$636K 0.1% 151
2020
Q1
$1.21M Buy
16,204
+1,845
+13% +$127K 0.08% 179
2019
Q4
$933K Sell
14,359
-3,271
-19% -$213K 0.05% 232
2019
Q3
$1.12M Buy
17,630
+11,697
+197% +$765K 0.08% 201
2019
Q2
$401K Sell
5,933
-281
-5% -$18.5K 0.02% 538
2019
Q1
$404K Sell
6,214
-266
-4% -$17.7K 0.02% 503
2018
Q4
$405K Sell
6,480
-12,330
-66% -$862K 0.03% 343
2018
Q3
$1.45M Buy
18,810
+667
+4% +$50.4K 0.05% 268
2018
Q2
$1.28M Sell
18,143
-28,632
-61% -$2.02M 0.05% 318
2018
Q1
$3.53M Buy
46,775
+1,469
+3% +$117K 0.11% 160
2017
Q4
$3.25M Buy
45,306
+7,431
+20% +$564K 0.09% 197
2017
Q3
$3.07M Buy
37,875
+5,354
+16% +$409K 0.08% 205
2017
Q2
$2.3M Sell
32,521
-8,399
-21% -$559K 0.07% 256
2017
Q1
$2.78M Sell
40,920
-18,676
-31% -$1.31M 0.09% 221
2016
Q4
$4.27M Buy
59,596
+18,628
+45% +$1.38M 0.12% 152
2016
Q3
$3.24M Buy
40,968
+4,555
+13% +$370K 0.13% 130
2016
Q2
$3.04M Sell
36,413
-7,141
-16% -$634K 0.14% 129
2016
Q1
$4M Buy
43,554
+3,988
+10% +$360K 0.18% 99
2015
Q4
$4M Buy
39,566
+5,287
+15% +$550K 0.18% 102
2015
Q3
$3.37M Sell
34,279
-15,465
-31% -$1.72M 0.29% 64
2015
Q2
$5.82M Sell
49,744
-14,656
-23% -$1.6M 0.29% 67
2015
Q1
$6.32M Buy
64,400
+43
+0.1% +$4.37K 0.14% 136
2014
Q4
$6.07M Sell
64,357
-3,601
-5% -$372K 0.37% 42
2014
Q3
$7.23M Buy
67,958
+6,005
+10% +$588K 0.47% 28
2014
Q2
$5.14M Buy
61,953
+10,405
+20% +$810K 0.34% 48
2014
Q1
$3.65M Buy
51,548
+16,456
+47% +$1.29M 0.3% 60
2013
Q4
$2.64M Buy
35,092
+6,019
+21% +$419K 0.26% 86
2013
Q3
$1.83M Sell
29,073
-998
-3% -$59.6K 0.22% 101
2013
Q2
$1.54M Buy
+30,071
New +$1.57M 0.2% 112

Other funds holding GILD

FDx Advisors's GILD Position: Q1 2026 in Review

FDx Advisors reduced its Gilead Sciences (GILD) stake by 36% in Q1 2026, selling an estimated $118K and leaving 1,481 shares worth $206K. The position accounts for 0.07% of the portfolio, ranked #178.

FDx Advisors first reported a position in GILD in Q2 2013 and has held it in 52 quarters since. The position peaked at $7.23M in Q3 2014. 2,311 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

  • FDx Advisors held 1,481 shares of Gilead Sciences worth $206K as of Q1 2026.
  • FDx Advisors sold 843 Gilead Sciences shares in Q1 2026, an estimated $118K.
  • Gilead Sciences made up 0.07% of FDx Advisors's portfolio in Q1 2026, its #178 holding.
  • FDx Advisors first reported a position in Gilead Sciences in Q2 2013 and has held it in 52 quarters since.
  • FDx Advisors's Gilead Sciences position peaked at $7.23M in Q3 2014.
  • 2,311 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on FDx Advisors's 13F filing for Q1 2026, filed 1 May 2026.